13 March 2020

New research model: mini-tumors of the kidney

Elize Brolsma

(News item via Princess Máxima Center)

Exciting new research from Oncode Investigator Jarno Drost (Prinses Máxima Center) on childhood kidney tumors.

Kidney tumors represent the second most common solid malignancy in children. Whereas the most common kidney tumor, Wilms tumor, is generally well treatable, the prognoses for non-Wilms tumors are usually very poor. Little progress has been made over the last years in the development of new, less toxic treatment options. This is partly caused by the lack of representative models that can be used for research purposes. The group of Jarno Drost succeeded in establishing organoid cultures, derived from a variety of different childhood kidney tumors, which can be used to study the biology of these tumors as well as to test new medication. These results have been published in Nature Communications.

All children with cancer in the Netherlands are treated In the Princess Máxima Center for pediatric oncology. As part of the treatment, (part of) the tumor is typically resected or a biopsy is taken for diagnostic purposes. The tumor tissue that remains is used for scientific research, provided that the parents consent. ‘That is a of course a difficult question for parents since they do not know what kind of research is actually performed with the tissue’, says Jarno Drost. ‘Our research demonstrates how valuable the material is for the generation of new research models of relatively rare tumors.’

‘The mini-tumors, or organoids, that we are now able to culture, are very similar to the tumor of the child’, explains Drost. The use of these mini-tumors may provide new insights in the origin of the tumor and the development of novel treatment.

Organoid of a Wilms tumor (credits: Ravian van Ineveld - Rios Group)

Team sport
The devil is in the details if it comes to culturing mini-tumors in the laboratory. ‘A lot of knowledge and skills have to come together to succeed’, says Drost. The temperature, composition of the air and growth medium have to be fine tuned to mimic the situation in the body. Only then the tissue can be kept alive as an organoid.

The findings of the research, performed by a team consisting of researchers and clinicians from the Princess Máxima Center, Hubrecht Institute, Oncode Institute and UMC Utrecht and supported by the Dutch Cancer Society and KiKa are published in Nature Communications.

Mini-tumors as model
The mini-tumors serve amongst others as model for testing drugs. Under the right circumstances, the Drost group now has an infinite amount of tumor cells to test the sensitivity of the tumor to large collections of medications and combinations.

In addition, the mini-tumors offer the opportunity to study the biology of the tumor in detail. ‘If we can figure out what makes a cell become malignant we might be able to find new therapeutic targets that specifically kill tumor cells and leave healthy cells unharmed’, he explains.

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.